The problem of body weight gain in HIV-infected patients during antiretroviral therapy


DOI: https://dx.doi.org/10.18565/epidem.2020.10.3.112-5

Kravchenko A.V., Kanestri V.G.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
The paper reviews the results of recent studies that establish a relationship between body weight gain in patients and use of drugs from the HIV integrase inhibitor (II) group. Over 60 years of age, female sex, African or Hispanic ethnicity, use of dolutegravir (mostly when combined with tenofovir alafenamide (TAF) versus other IIs/protease inhibitors (PIs)/nonnucleoside reverse transcriptase inhibitors (NNRTIs), as well as antipsychotic medication intake, low baseline CD4+ lymphocyte counts, and a high viral load were associated with large body weight gains or body mass index (BMI) changes. Body weight gain in patients during antiretroviral therapy (ART) increased the risk of developing type 2 diabetes mellitus and cardiovascular diseases. The impact of using a second-generation NNRTI (such as doravirine) as part of a first-line ART regimen was comparable to that of the ART regimens including PI or efavirenz (EFV). Further investigations are needed to clarify the influence of individual factors and their combination on BMI and a risk for somatic diseases.
Keywords: higher BMI increase, Keyword: HIV infection, antiretroviral therapy
Read entire article

Literature

1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). 18 December, 2019. https://www.AIDSinfo.nih.gov


2. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 10.0; November, 2019). European AIDS Clinical Society http://www.eacsociety.org


3. ВОЗ. Обновление рекомендаций по антиретровирусной терапии первой и второй линии. Женева, Швейцария, 2019 (WHO/CDS/HIV/19.15). Лицензия: CC BY-NC-SA 3.0 IGO. http://apps.who.int/iris

[WHO. Updating recommendations for first-and second-line antiretroviral therapy]. Geneva, Switzerland, 2019 (WHO/CDS/HIV/19.15). License: CC BY-NC-SA 3.0 IGO. http://apps.who.int/iris


4. Koethe J.R., Jenkins C.A., Lau B., Shepherd B.E., Justice A.C., Tate J.P. et al. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Research and Human Retroviruses 2016; 32(1): 55–8. DOI: 10.1089/aid.2015.0147


5. Sax P.E., Erlandson K.M., Lake J.E., McComsey G.A., Orkin C., Esser S. et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin. Infect. Dis. 2019; XX(XX): 1–11. DOI: 10.1093/cid/ciz999


6. Hill A., McCann K.M., Pilkington V., Moorhouse M.A., Sokhela S., Serenata C.M. et al. Risks of metabolic syndrome, diabetes, and cardiovascular disease in advance trial. Conference on Retroviruses and Opportunistic Infections (CROI). USA, Boston, 8–11 March 2020. Abstract 81, p. 28. www.croiconference.org


7. McCann K., Moorhouse M., Sokhela S., Venter W.D.F., Serenata C., Qavi A. et al. The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC + DTG compared to TDF/FTC + DTG, and TDF/FTC/EFV. EACS 2019. HIV Medicine 2019; 20(Suppl. 9). Abstract book, Abstract PS3/3, p. 8.


8. Rebeiro P.F., Jenkins C., Bian A., Lake J.E., Bourgi K., Althoff .K.N. et al. Diabetes, weight gain, and integrase inhibitor use in North American HIV+ persons. Conference on Retroviruses and Opportunistic Infections (CROI). USA, Boston, 8–11 March 2020. Abstract 680, p. 248. www.croiconference.org


9. Burdet C., Peytavin G., Le M., Landman R., Bachelet D., Katlama C. et al. Drug concentrations and body weight gain in plwh switched to 3TC & Dolutegravir (DTG). Conference on Retroviruses and Opportunistic Infections (CROI). USA, Boston, 8–11 March 2020. Abstract 677, p. 247. www.croiconference.org


10. Orkin C., Elion R., Thompson M., Rockstroh J., Xu Z.J., Martin E.A. Effect of doravirine on body weight and body mass index in treatment naıve adults with HIV-1. EACS 2019. HIV Medicine 2019; 20(Suppl. 9). Abstract book. Abstract PS3/2, p. 7–8.


About the Autors

Prof. Alexey V. Kravchenko, MD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: a.kravchenko@hiv-russia.ru; ORCID: http://orcid.org/ 0000-0001-7867-3763
Veronika G. Kanestri, MD, Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: kanestri@yandex.ru; ORCID: http://orcid.org/0000-0002-2234-7094


Similar Articles

Back to Content

Бионика Медиа